FDA Clears Siemens Healthineers’ AI Coronary Plaque Analysis Software, Syngo.CT Coronary Cockpit

Siemens Healthineers has received FDA clearance for Syngo.CT Coronary Cockpit, software that uses AI-based segmentation to measure and characterize coronary plaque from CT angiography scans and to support planning of stent procedures.

Christopher Ort
By i10X News Desk · Reviewed by Christopher Ort · 3 min read
Share
A cardiologist with a tablet stands beside a CT scanner in a bright hospital imaging room.
Image: AI-generated, i10X
On this page
  1. Quick Take
  2. In plain English
  3. What happened
  4. Background
  5. Why it matters
  6. What's still open
  7. About the analysis
  8. i10x Perspective

Siemens Healthineers has received clearance from the US Food and Drug Administration for Syngo.CT Coronary Cockpit, software that uses AI to analyze coronary plaque in CT scans of the heart. The tool is meant to help clinicians judge a patient’s risk and decide whether a stent procedure or medical treatment is the better path, using coronary CT angiography (CCTA) data from any CT scanner.

i10X Quick Take

Quick Take

  1. The product: Syngo.CT Coronary Cockpit, part of the Syngo.via imaging software platform.
  2. The AI: AI-based segmentation, labeling and visualization of plaque across the entire coronary tree or within individual lesions.
  3. The use: Assessing plaque amount, composition, size and distribution, and planning percutaneous coronary intervention (PCI).
  4. Compatibility: Works with CCTA data from any CT scanner, with extra benefits on Siemens Healthineers dual-source and photon-counting systems.
  5. Status: FDA cleared, announced November 19, 2026.

In plain English

Heart attacks are often caused by fatty deposits, called plaque, in the arteries that feed the heart. A CT scan can show that plaque without a catheter, but measuring it by hand is slow. This software lets AI outline and measure the plaque automatically, so doctors get a detailed picture faster and can decide whether a patient really needs an invasive procedure.

What happened

Siemens Healthineers announced the FDA clearance in a press release. The company says the software “provides advanced, automated analysis of coronary plaque, enabling access to critical details in cardiac CT images to support clinical decision-making and percutaneous coronary intervention (PCI) planning.”

“With Syngo.CT Coronary Cockpit, clinicians can obtain advanced insights from a patient’s CT scan to support a more comprehensive assessment of cardiac health and better inform treatment decisions,” said Olivia Egan, head of Computed Tomography at Siemens Healthineers North America.

The company notes that patients with suspected or known coronary artery disease often undergo invasive diagnostic procedures in the cath lab that could have been avoided with more information. Citing published studies, it says CCTA on its Naeotom Alpha photon-counting CT scanner can reduce diagnostic angiography referrals by more than 50% and lower costs and hospital stays.

Background

Coronary artery disease is the most common form of heart disease, which is the leading cause of death in the US and worldwide, according to the US Centers for Disease Control and Prevention as cited by Siemens Healthineers. Radiology and cardiology account for the bulk of AI-enabled medical devices cleared in the US, a trend tracked in our FDA AI Medical Device Tracker.

Why it matters

Plaque analysis has long been possible but labor intensive, which limits how often it is used in routine care. An FDA-cleared AI tool that works with scans from any CT vendor lowers that barrier and could help steer more patients toward noninvasive diagnosis. For Siemens Healthineers, it also strengthens the case for its photon-counting scanners in cardiac imaging.

What’s still open

  • Which clinical validation data supported the FDA clearance.
  • Pricing and when the software will be broadly available to US hospitals.
  • How results compare with other cleared plaque analysis tools in head-to-head use.

About the analysis

This independent i10x analysis is based on the Siemens Healthineers press release. Quotes are taken from that release.

Sources (plain text, no links):

  • Siemens Healthineers press release: “Siemens Healthineers Receives FDA Clearance for Syngo.CT Coronary Cockpit Arterial Disease Management Software” (Malvern, Pa., November 19, 2026)

i10x Perspective

Imaging AI keeps moving from detection to decision support. More on our Health & Medical Research page, where recent research also shows the limits of AI agents reading CT and MRI scans.

Christopher Ort

Christopher Ort

Christopher Ort is the editor of i10X News at i10x.ai. He has worked hands-on with AI tools, models and agent workflows for years and leads i10X’s coverage of AI launches, funding and research. He is the author of “The Style Penalty”, an SSRN study on how frontier AI models judge AI-written CVs, covered by heise online and t3n.

Editor's picks

  1. Georgia Tech’s Academic AI Playbook: 20 Lessons From 67 Real Courses, Free to Reuse
  2. Arcfront’s $1B Run Rate: What the AI Data Startup Confirms and What It Doesn’t
  3. GPT-6.2 Astra Tops Blueprint-Bench 2, 70% Above May Leader GPT-5.5
  4. Deutsche Telekom Puts 100 Million Euros Into Mistral for Sovereign AI in Germany
  5. Inkling 2 Mini: Thinking Machines’ Looped Open Model Tops Qwen on Coding Tests